Relatox Shows Promise in Reducing Chronic Migraine Days
- MigraineMind
- 3 hours ago
- 1 min read
Research Summary
A recent study published in Zh Nevrol Psikhiatr Im S S Korsakova explores the use of Relatox, a botulinum toxin type A, for treating chronic migraines. Conducted at a specialized headache center, the study involved 150 participants with an average age of 39 years. Notably, 40% of these patients had previously not responded to other migraine medications. Relatox was administered every 12 weeks, resulting in a significant reduction of migraine days from 24 to 14 days. Impressively, 61% of patients experienced a ≥30% reduction in migraine days, and 48% saw a ≥50% reduction. Adverse events were minimal, occurring in 3% of patients.
Study Details
👥 Research Team: Azimova YE et al.
📚 Published In: Zh Nevrol Psikhiatr Im S S Korsakova
📅 Publication Date: 2025
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.